Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
We have isolated various bioactive peptides
2022-05-30

We have isolated various bioactive o6 acting by binding to the receptors of endogenous bioactive peptides such as opioid, bradykinin, neurotensin, and complements C3a and C5a etc. [24]. Rubimetide is the first example of an agonist peptide of the FPR2 of exogenous origin. Anxiolytic-like activity
88 3 sale This excellent tolerability is especially interest
2022-05-30

This excellent tolerability is especially interesting in the light of the fact that intravenous administration of liposomal ponatinib was predicted to yield much higher plasma concentrations as compared to the orally administered free drug. In addition, liposomal drug dose in absolute numbers was te
br Ferroptosis modulators With the recognition that the smal
2022-05-30

Ferroptosis modulators With the recognition that the small molecule erastin targets system xc- and thereby specifically triggers this form of death and that ferrostatin-1 prevents erastin-induced ferroptosis [2], it has become evident that ferroptosis is a druggable pathway with a number of tract
The exact mechanism by which N BPs inhibit FPPS
2022-05-30

The exact mechanism by which N-BPs inhibit FPPS remains unclear. Computer modeling [10] suggests that N-BPs mimic the structure of the enzyme’s natural isoprenoid pyrophosphate substrates, geranyl pyrophosphate (GPP)/dimethylallyl pyrophosphate (DMAPP) or act as carbocation transition state analogs
br Drugs approved or in development To date
2022-05-30

Drugs approved or in development To date, three drugs: RAL (MK-0518), EVG (GS-9137) and DTG (GSK1349572) [104], have been approved by the FDA. Their structures are shown in Fig. 5. DTG is under development by GlaxoSmithKline (GSK), and studies have shown DTG to be effective in patients with resis
Two US FDA approved assays are commonly used for
2022-05-30

Two US FDA-approved assays are commonly used for VL monitoring: the COBAS AmpliPrep/COBAS® Taqman® HIV-1 version 2.0 (“CAP/CTM HIV-1 v2”; Roche Molecular Systems) [18], and the RealTime HIV-1 assay (“RealTime HIV-1”, Abbott Molecular) [19]. Several studies have shown good correlation between the ass
Recent studies have also identified additional proteins that
2022-05-30

Recent studies have also identified additional proteins that could act as scaffolds and promote the interaction of core Hippo pathway components. APC, which is best known as a key component of the β-catenin destruction complex, was observed in mammalian (R)-baclofen synthesis to have an additional
The overall response rate to afatinib
2022-05-30

The 13% overall response rate to afatinib is comparable to a 19% response rate reported by Peters et al. [20] in a separate retrospective series investigating the use of afatinib in more heavily pretreated patients with HER2-mutant lung adenocarcinomas. Our 13% response rate is also comparable to an
In summary P P macrocyclization proved to be an
2022-05-30

In summary, P2-P4 macrocyclization proved to be an effective strategy to drive activity in this series of HCV NS3 protease inhibitors while microsomal stability was enhanced by the introduction of steric bulk along the tether. This modification augmented the previously-described tactic of improving
The eel and perhaps other euryhaline teleost fish have
2022-05-30

The eel, and perhaps other euryhaline teleost fish, have the additional peptide, renoguanylin that exhibits high levels of expression within the kidney as well as the intestine. In terms of overall sequence, pre-prorenoguanylin is more homologous to pre-proguanylin than pre-prouroguanylin and a phen
br Introduction The discovery that
2022-05-30

Introduction The discovery that the nitric oxide (NO), soluble guanylate cyclase (sGC), and cyclic guanosine monophosphate (cGMP) pathway mediates erection has led to the use of phosphodiesterase type 5 (PDE-5) inhibitors as the gold standard for treating erectile dysfunction (ED) through the inh
Activity of compound in rat brain tissue highlights the
2022-05-30

Activity of compound 10 in rat hydroxychloroquine sulfate tissue highlights the potential to use this new class of allosteric sGC inhibitors to study the role of the NO—sGC—cGMP signalling pathway in the brain. Reducing amounts of cGMP in cells would have implications in downstream signalling prote
In order to determine whether NF
2022-05-30

In order to determine whether NF-κB could interact with GSTP1-1 promoter, we performed EMSA. One NF-κB like (−98κB) binding site was previously described in the GSTP1-1 promoter as a regulator element. However, few data about this site have been published and its role in the GSTP1-1 gene regulation
Acknowledgments Financial support from the National Natural
2022-05-30

Acknowledgments Financial support from the National Natural Science Foundation of China (81730094, 81473262 and 81573299) is gratefully acknowledged. This project was also supported by the “111 Project” from the Ministry of Education of China, the State Administration of Foreign Expert Affairs of C
br Material and methods br Results
2022-05-30

Material and methods Results Consistent with our previous study, SR-SIM and confocal microscopy showed a large number of IBA1-expressing SB 242084 in all parts of the human cochleae (Fig. 1). IBA1, the microglial and macrophage-specific calcium-binding protein, is involved in the membrane ruf
8158 records 463/544 page Previous Next First page 上5页 461462463464465 下5页 Last page